FibroGen is pioneering oncology and rare disease therapies that expand what is possible. Our mission is to advance the development of innovative treatments at the frontiers of cancer biology and rare disease. We are developing potential first-in-class medicines for life-altering and life-threatening conditions, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC).